Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Micro Cap & Branchenriese: Heute rein? - Partnerschaft entfacht Übernahmefantasien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E1Z1 | ISIN: US2933062059 | Ticker-Symbol: 4EG0
Berlin
30.11.23
21:52 Uhr
0,223 Euro
0,000
0,00 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
ENGLOBAL CORPORATION Chart 1 Jahr
5-Tage-Chart
ENGLOBAL CORPORATION 5-Tage-Chart
ACCESS Newswire
208 Leser
Artikel bewerten:
(1)

ENGlobal Announces Third Quarter 2024 Financial and Operating Results

Finanznachrichten News

HOUSTON, TX / ACCESSWIRE / November 12, 2024 / ENGlobal Corporation (NASDAQ:ENG), a provider of innovative engineering project solutions focused on the energy industry, today announced it has filed its third quarter 2024 report on Form 10-Q with the U.S. Securities and Exchange Commission for the three-months ended September 28, 2024. The report details ENGlobal's financial and operational results.

Revenues for the three months ended September 28, 2024 were $5.7 million compared to $9.5 million for the same period in 2023. Net loss improved for the quarter by $0.2 million to $0.5 million from a net loss of $0.7 million for the same period a year ago.

Results for the three-month periods include a non-recurring revenue adjustment of $1.5 million in 2023 and a lease impairment adjustment of $0.9 million in 2024. Excluding these adjustments, gross profit percentage for the quarter increased by 87% to 8.4% from 4.5%, and SG&A decreased by $0.7 million to $1.8 million from $2.5 million, which resulted in a net loss improvement of $0.8 million to $1.4 million from $2.2 million.

"We continue to make sequential improvements in operating efficiency as our gross margin percentage improved and we reduced SG&A costs for the third consecutive quarter," said William A. Coskey, P.E., ENGlobal's Founder, Chairman and Chief Executive Officer. "We continue to work diligently to grow our book of business across all segments."

Revenues for the nine months ended September 28, 2024 were $18.4 million compared to $32.4 million for the same period in 2023. Net loss improved by $8.3 million to $3.1 million from a net loss of $11.4 million for the same period a year ago.

"We continue to work toward strategic opportunities to gain scale and find partnerships that will provide value for ENGlobal shareholders," added Coskey. "We believe that the results from the recent election will provide a path forward to meet our strategic objectives."

"While we have made significant progress on repositioning ENGlobal, we still have work to do in the coming weeks and months," concluded Coskey. "Over the course of the remainder of 2024, our focus is on further strengthening the financial and operating position of the company and working hard to execute on strategic opportunities that add tangible value for our shareholders."

ENGlobal's comprehensive financial statements can be found in the Company's quarterly report filed on Form 10-Q with the U.S. Securities and Exchange Commission.

About ENGlobal

ENGlobal Corporation (NASDAQ:ENG) is a provider of innovative, delivered project solutions primarily to the energy industry. ENGlobal operates through two reportable segments: Commercial and Government Services. The Commercial segment provides engineering, design, fabrication, construction management and integration of automated control systems. The Government Services segment provides engineering, design, installation, operations, and maintenance of various government, public sector, and international facilities, specializing in turnkey automation and instrumentation systems for the U.S. Defense industry. Further information about the Company and its businesses is available at www.englobal.com.

For further information, please email ir@englobal.com.

Cautionary Note Regarding Forward-Looking Statements

The statements above regarding the Company's expectations, including those relating to its future results, its future operations and certain other matters discussed in this press release may constitute forward-looking statements within the meaning of the federal securities laws and are subject to risks and uncertainties. For a discussion of risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ENGlobal's filings with the Securities and Exchange Commission, including the Company's most recent reports on Form 10-K and 10-Q, and other SEC filings.

SOURCE: ENGlobal



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.